week 9- thyroid and hepatis Flashcards

1
Q

• What is rT3 (reverse T3)?

A

o Usu ↑ in hypothyroidism
o help dx “sick thyroid” pts (who are euthyroid) from true hypothyroid cases
o in a body under stress (illness, fasting, high cortisol) T4 is deiodinized to rT3 instead of T3
o (“step down”, instead of “step up”)= (-) charge in diff spot
o Metabolic enzyme function ↓ → Stresses inhibit 5’-deiodinase → ↓ T4 to T3, ↑ rT3
o Sxs of Wilson’s (temp) syndrome: hypothyroid, ↑rT3, corrected by giving T3 (Not accepted by mainstream)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

• What is significance of BBT?

A

o reflects metabolic rate controlled by thyroid hormones
o N = 97.6-98.2 F
o Menstruating females take BBT on d2-4 of menses
o ↓ quite common, may = hypothyroidism
o ↑ BBT less common, may = hyperthyroidism
o Look for other sxs thyroid dz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

• What are thyroid antibodies? Risk factors?

A

o =auto-Abs
o Stimulating: a-Thyroid receptor =Thyroid stimulating Igs (TSI)
o Blocking: a-thyroperoxidase (a-TPO); Thyroglobulin (a-TGLB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

• What is Graves dz?

A

o MC cause hyperthyroid (80-85%)
o dt stimulation of TSHRs by TSI, over stimulate thyroid activity
o Abs arise 2nd to defect in T-suppressor cells → clone of T-helper to interact with thyroid Ags → stimulate B cells to make TSI
o a-TPO and a-TGLB often seen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

• what are ssx of graves?

A
o	→ sympatho-adrenergic activity and metabolism
o	↓ TSH, ↑ T3/T4
o	Exophthalmos
o	Warm pulsating goiter
o	Tachycardia
o	Fine tremor (hand)
o	Pretibial myxedema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

• how is Graves diagnosed?

A

o ↑T3, T4; ↓TSH

o gland non-palpable or smooth symmetric goiter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

• Describe fetal thyroid development, and how it’s affected by Graves?

A

o fetus dependent on mom’s T4 until 10-12 wks
o 20 wks, responsive to its own TSH, low thyroid function
o IgG Abs in Graves cross placenta → fetal hyperthyroid after 20 wks gestation
o Antithyroid drugs (methimazole, propylthiouracil) also cross placenta → tx both maternal and fetal hyperthyroid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

• What is RAIU (radioactive iodine uptake)?

A

o Scintillation counter measures radioactivity 6 & 24 hrs after I(123) given
o Uptake varies greatly by iodine status: Indigenous diet (normal uptake 10% vs 90%); Amiodarone, Contrast study, Topical betadine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

• What causes abnormal RAIU results?

A

o Sx ↑: Graves, Toxic goiter
o Sx ↓: Thyroiditis (Subacute, Active Hashimoto’s), Hormone ingestion (Thyrotoxicosis factitia, Hamburger Thyrotoxicosis); Excess I- intake in Graves’ (Jod-Basedow effect); Ectopic thyroid carcinoma (Struma ovarii)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

• What is hashimoto’s thyroiditis?

A
o	MC cause acquired primary hypo
o	mb caused by any environmental trigger
o	F>M,  8:1; Onset usu 30-50 
o	FHx common
o	Early stages may present as hyper
o	Early labs may show normal T4 and TSH, ↑ a-TPO, and less commonly a-Tg
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

• How is hashimoto’s diagnosed?

A

o RAIU mb ↑ or ↓
o Later: hypo, ↓T4, T3RU, ↑TSH, ↓ RAIU dt gland destruction
o Ab titers much higher in thyroiditis than Grave’s
o Gland mb TTP dt inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

• What is Euthyroid sick syndrome?

A

o T4/T3 ↓ in acute & chronic illness (any severe), fasting, starvation, sepsis, surgery, MI, BM transplant
o Abn tests w acute or chronic non-thyroidal systemic illness
o Secondary to:
o ↓ peripheral conversion T4 T3
o ↓ clearance rT3
o ↓ binding T3/T4 to TBG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

• What are common causes of ESS w fidnings?

A

o NTI (MC): ↓T3; N TSH, T4; mb dt ↓ T3 →4
o 20% ICU pts: ↓T3/T4; N TSH; mb dt ↓ TBG, albumin
o severe illness: ↓TSH, T3/T4; HTH and Pit involved
o cirrhosis, hepatitis, acute psych: ↑ T4; TSH & T3 N or ↑

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

• what are screening recommendations for thyroid dz in adults?

A

o USPSTF: say insufficient evidence for or against routine screening
o AAFP: high-risk populations: F w FHx thyroid dz, F >35, prego, abd PE, DM, AI Hx
o ATA: start at a 35 (+ q5 yrs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

• What are some good and not-so-good indications to screen for hypothyroid?

A

o High suspicion: goiter, delayed reflexes
o Intermediate: Fatigue, wt gain/difficulty losing wt, Cold intolerance, Dry, rough, pale skin, Constipation, FHx, Hoarseness
o Low, non-specific sxs: Coarse, dry hair, Hair loss, Muscle cramps/aches, Depression, Irritability, Memory loss, Abn menstrual cycles, ↓ libido

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

• What are some good and not-so-good indications to screen for hyperthyroid?

A

o High: goiter, thyroid bruit, lid lag, proptosis
o Med: Fatigue, Wt loss despite ↑appetite, Heat intolerance/sweating, Fine tremor, FHx, ↑BMs, ↑HR/palpitations, Staring gaze
o Low: Nervousness, Insomnia, Breathlessness, Light or absent menstrual periods, Wt loss, Muscle weakness, Warm moist skin, Hair loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

• What is recommended prenatal thyroid screening?

A

o Universal screening before preg not recommended
o Prenatal serum TSH testing is recommended if high risk or known thyroid dysfunction
o Non-Consensus on TSH screening for all prego vs high-risk at time of first visit or by 9th wk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

• What is neonatal thyroid screening for congenital hypothyroid?

A

o All infants screened at 2-4 d
o congenital hypo usu unaffected at birth, dt placental transfer of T4; but must get tx by 2-3wks
o otherwise → mental retardation
o if mom is hypo, significant impairment of neurointellectual development despite early tx
o 3 screening strategies: (1) primary TSH, backup T4 in infants w ↑ TSH, (2) primary T4, backup TSH w ↓T4, (3) both T4 and TSH (IDEAL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q
  • Total T4: ↑
  • T3RU: ↑
  • FTI: ↑
  • TSH: ↓
  • FT4: ↑
  • Total T3: ↑
A

o Primary hyper

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q
  • Total T4: ↓
  • T3RU: ↓
  • FTI: ↓
  • TSH: ↑
  • FT4: ↓
  • Total T3: ↓/N
A

o Primary hypo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q
  • Total T4: ↑
  • T3RU: ↓
  • FTI: N
  • TSH: N
  • FT4: N
  • Total T3: N
A

pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

• What is viral hepatitis?

A

o 5 viruses, A-E
o affinity for hepatocyte, induce liver injury, usu immune-mediated mechanism
o Diff physical,chemical composition, mechanisms to replicate within infected cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

• Hx of viral hepatitis?

A

o Contagious jaundice, 8th century, Pope Zacharias ordered isolation of affected
o Virchow, 1865, epidemic jaundice dt mucous plug in the papilla of Vater
o early 20th century linking vaccination, blood drawing, blood transfusion and parenteral tx of syphilitic pts w contaminated needles, development of “serum hepatitis”
o WW II, >200,000 cases of jaundice in american, >5 million cases in germans
o MacCallum 1940’s, suggested both enteric (“infectious hepatitis”, “hepatitis A”) and parenteral/sexual (“serum hepatitis”, “hepatitis B”) transmission could occur
o mid-20th century, “A & B” had diff clinical courses, suggesting different etiologies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

• What was the Willowbrook state school’s role in elucidating hepatitis viruses?

A

o 1950s and 60s: 1000s of intellectually disabled children, mostly w trisomy 21 →jaundice freq, ↑ LFTs; Newly admitted children exposed to infectious material, w parental consent → criticism
o found diff filterable infx agents caused 2 clinical patterns of hepatitis
o One inoculum of serum (MS1, initials of infected child) → illness, short inc, like epidemic hepatitis (A)
o Another, MS2 (same child who later developed the 2nd form of jaundice) →illness, longer inc, like B
o Boggs used MS1 in Marmoset monkeys (1967), Humans incarcerated at Joliet State Penitentiary (US Army 1970)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

• How was hepatitis B discovered?

A

o 1963, Dr. Baruch Blumberg (nobel prize 1976), identified a protein (“Australia Ag” reacted to Abs from pts w hemophilia and leukemia
o Assoc w infx hepatitis 1966
o virus specifically seen by electron microscopy in 1970

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

• how was hepatitis A discovered?

A

o 1973, NIH, in fecal samples from ppl inoculated w MS1 serum from Willowbrook
o Electron microscopy: 27 nm spherical viral particles, aggregates after incubation of fecal samples w convalescent serum
o successfully adapted to grow in culture by end of 1970’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

• how was hepatitis D discovered?

A

o 1977, Rizetto in Turin, identitied new Ag in both liver and serum in carriers of HBsAg
o HDV= defective virus, genome is negative circular ssRNA, encodes single nucleocapsid protein (delta Ag)
o To replicate, Requires envelope of HBV w HBsAg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

• How was hepatitis C discovered?

A

o End of 1970’s, found most cases of post-transfusion hepatitis were not dt A, B, D (20% dt cardiac surgery w blood transfusion)
o known as non-A, non-B hepatitis (NANBH)
o identified by Houghton, 1989, Chiron Corporation
o Retrospective testing showed 90% of non-A, non-B hepatitis was HVC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

• What is hepatitis E?

A

o epidemic waterborne, similar to A
o first recognized in India in 1980
o Causative agent identified in Uzbekistan in 1983
o Genome cloned in 1990 and fully sequenced shortly after

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

• What are “infectious” and “serum” viral hepatitis? NANB?

A

o Infectious: became known as HAV
o Serum: B, D
o NANB: E (enterically transmitted), C (parenterally transmitted), F, G?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

• What are sources of virus for the 5 hep viruses? Route of transmission?

A

o A, E: feces
o B, C, D: blood/blood-derived body fluids
o A, E: fecal, oral
o B, C, D: percutaneous, permucosal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

• Which of the 5 hep viruses can be chronic infx? How are they prevented?

A

o Chronic: B, C, D
o A, B: pre/post-exposure immunization
o C: blood donor-screening; risk behavior modification
o D: pre/post-exposure immunization; risk behavior modification
o E: ensure safe drinking water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

• What is the hepatitis A virus?

A

o Naked RNA virus
o Related to enteroviruses, formerly known as enterovirus 72, now put in its own family: heptovirus
o One stable serotype only
o Difficult to culture: primary marmoset cell culture, also in vivo in chimpanzees and marmosets
o 4 genotypes exist, but in practice most of them are group 1

34
Q

• How is hepatitis A spread?

A

o Close personal contact household, sexual, day care)
o Contaminated food, water (infx food handlers, raw shellfish)
o Blood exposure (rare) ( IV drugs, transfusion)

35
Q

• What is the geographic distribution of HABV infx?

A

o High: S and Central America, Africa, Greenland, Middle East, South Asia
o Med: S and E Europe, North Eurasia
o Low: N America, Australia
o Very low: N Europe

36
Q

• What are clinical features of hepatitis A?

A

o Inc: avg 30 d (r 15-50)
o Jaundice: 10% < 6, 40-50% 6-14, 70-80% > 14
o Comp: fulminant, cholestatic, relapsing hepatitis
o Chronic sequelae: none

37
Q

• How is HAV diagnosed?

A

o Acute: serum HAV-IgM by EIA
o Immunity: HAV-IgG by EIA.
o Cell culture: difficult, up to 4 wks, not routine
o Direct Detection: EM, RT-PCR of feces. detect earlier than serology but rarely done

38
Q

• What is the typical serological course of hepatitis A?

A

o Fecal HAV peaks @ 1-3 mos (correlated w sxs)
o ↑ ALT 1-3 mos?
o IgM a-HAV present 1-5 mos
o Total a-HAV plateaus after 1 ye (IgG)

39
Q

• What does CDC say about HAV prevention?

A
o	Vaccine is primary 
o	2006: Universal infant vaccination 
o	1996, Adults w ↑ risk infx or its adverse consequences:
o	Traveler to HAV endemic country
o	MSM
o	Illegal drugs 
o	chronic liver dz 
o	clotting factor dos
40
Q

• what is the hepatitis B virus?

A

o dsDNA virus (+ strand not complete)
o Replication involves a reverse transcriptase
o Complete Dane particle 42 nm, 28 nm electron dense core, w HBcAg and HBeAg. coat and 22 nm free particles contain HBsAg
o At least 4 phenotypes of HBsAg: adw, adr, ayw and ayr.
o HBcAg is single serotype
o HBV has 8 genotypes (A-H): A and C predominate in US, B and D also present. Genotype F in S America and Alaska. A, D, E in Africa. D in Russia (USSR), B and C in Asia
o Can’t culture

41
Q

• What are the relative concentrations of HBV in diff body fluids?

A

o High: blood, serum, wound exudates
o Mod: semen, vaginal fluid, saliva
o Low/not detectable: urine, feces, sweat, tears, breast milk

42
Q

• What is the geographic distribution of chronic HBV infection?

A

o High: Alaska, N Canada, S Greenland, N Brazil, Africa, Asia
o Med: Brazil, N Africa, E Europe, Middle East
o Low: N America, Argentina, N Greenland, N Europe, Australia

43
Q

• Describe the structure of the hepatitis viruses:

A

o A: ssRNA → capsid
o B: (elongated or spherical) dsDNA (partial ss) →HBeAg →HBcAg →nucleocapsid →envelope (lipid from host cell) → HBsAg
o C: ssRNA →nucleocapsid →envelope → glycoproteins
o D: tiny ssRNA → small and large delta Ag → HBsAg
o E: ssRNA → unenveloped, 32-34nM

44
Q

• What are clinical features of hepatitis B?

A
o	Inc: avg 60-90 d (r 45-180)
o	Jaundice: 10% < 5, 30-50% > 5
o	Acute fatalitiy: 0.5-1%
o	Chronic: 30-90% < 5, 2-10% > 5
o	mortality dt chronic liver dz: 15-25%
45
Q

• what is typical serologic course of acute HBV w/o chronic progression?

A
o	HBsAG 4-24 wks (correlated w sxs)
o	IgM a-HBc 6-32 wks
o	a-HBs after 32 wks
o	HbeAg: 4-12 wks
o	a-HBe: after 12 wks
o	total a-HBc plateaus at 16 wks
46
Q

• what is typical serologic course of chronic HBV?

A
o	HBsAg plateaus at 12 wks
o	Total a-HBc plateaus at 16 wks
o	IgM a-HBc 6-36 wks
o	HBeAg: 6wks – yrs
o	a-HBe mb seen yrs later
47
Q

• how is hepatitis B diagnosed?

A

o HBsAg: general marker of infx
o HBsAb: document recovery/immunity
o a-HBc IgM: marker of acute
o a-HBc IgG: past or chronic
o HBeAg: indicates active replication = infectiveness
o a-Hbe: virus no longer replicating. Mb (+) for HBsAg, made by integrated HBV
o HBV-DNA: indicates active replication, more accurate than HBeAg esp in cases of escape mutants. monitoring response to tx

48
Q
  • HBsAG: (-)
  • Total a-HBc: (-)
  • IgM a-HBc: (-)
  • a-HBs: (-)
A

o never infected

49
Q
  • HBsAG: (+)
  • Total a-HBc: (-)
  • IgM a-HBc: (-)
  • a-HBs: (-)
A

o early acute, or transient after vaccine

50
Q
  • HBsAG: (+)
  • Total a-HBc: (+)
  • IgM a-HBc: (+)
  • a-HBs: (-)
A

o acute

51
Q
  • HBsAG: (-)
  • Total a-HBc: (+)
  • IgM a-HBc: (+)
  • a-HBs: (-)
A

o acute resolving

52
Q
  • HBsAG: (-)
  • Total a-HBc: (+)
  • IgM a-HBc: (-)
  • a-HBs: (+)
A

o recovered from past infx and immune

53
Q
  • HBsAG: (+)
  • Total a-HBc: (+)
  • IgM a-HBc: (-)
  • a-HBs: (-)
A

o chronic infx

54
Q
  • HBsAG: (-)
  • Total a-HBc: (-)
  • IgM a-HBc: (-)
  • a-HBs: (+)
A

o vaccine immunity

55
Q

• what are possible outcomes HBV infx?

A

o Acute
o → chronic: 3-5% of adult-acquired, 95% infant-acquired
o → chronic hepatitis: 12-25% in 5 yrs
o HCC 6-15% in 5 yrs → death or transplant
o Liver failure, 20-23% in 5 yrs → death or transplant

56
Q

• What is HBV infx?

A

o >200 million carriers worldwide
o Established cause of chronic hepatitis and cirrhosis
o Human carcinogen: cause up to 80% HCC

57
Q

• Who gets chronic HBV dz?

A

o Rule of thumb, the younger the age, the more likely to become chronic
o Neonates: 95% chronic, most asx
o Infant-6 yrs: 30% chronic
o >6: 3-5% chronic

58
Q

• What is HBV perinatal transmission?

A

o *in the absence of postexposure prophylaxis
o If mother (+) HBsAg and HBeAg: 70%-90% of infants infx → 90% become chronic
o If (+) HBsAg only: 20% of infants infected → 90% become chronic

59
Q

• What is the strategy to eliminate HBV transmission?

A

o (Advisory Committee on Immunization Practices CDC)
o Prevent perinatal HBV transmission
o Universal infant vaccination
o Catch-up vaccination of all children and adolescents <19 years
o Vaccination of adults in high risk groups

60
Q

• What is the HDV?

A

o delta agent = defective virus, like viroids in plants
o 35 nm particle w delta antigen surrounded by outer coat of HBsAg
o tiny ssRNA genome

61
Q

• what are clinical features of HDV infx (w HBV)? How is it spread?

A

o Co-infection: severe acute dz, low risk chronic
o Super-infection: usu chronic, high risk severe chronic liver dz, may present as acute
o Spread: percutaneous exposure (IV drugs), per-mucosal (sex)

62
Q

• What is the typical serologic course of HBV-HDV co-infx?

A

o Weeks after exposure: HBsAg, HDV RNA, IgM-HDV (+total) peak then drop (assoc w sxs, ↑ ALT)
o anti-HBs then rises and plateaus

63
Q

• what is typical serologic course of HBV-HDV superinfx?

A
o	Similar to co-infx
o	Esp jaundice as sx
o	HDV RNA and HBsAg persist
o	total a-HDV persists (IgM never disappears, IgG rises and plateaus)
o	ALT oscillates
64
Q

• What are sequelae of HBV-HDV infxs?

A
o	Co (in healthy ppl): 3-4% fulminant, death; 90% recovery w immunity; rare chronic HBV/HDV hepatitis, cirrhosis
o	Super (HBV carrier): 7-10% fulminant, death; 10-15% acute, severe, recovery; 80% chronic HBV/HDV, cirrhosis
65
Q

• What is geographic distribution of HDV infx?

A

o High: brazil, some Africa, some Europe
o Med: some Africa, middle east
o Low: N America, argentina, some Africa, Europe, india, Australia
o Very low: Alaska, brazil, South Africa, china
o Lots of “no data”

66
Q

• What are recommendations for HDV prevention?

A

o Co: Pre or post-exposure prophylaxis to prevent HBV

o Super: Education to reduce risk behaviors in chronic HBV pts

67
Q

• What is the HCV?

A

o Genome like a flavivirus, (+) ssRNA, 10,000 bases, enveloped, 30-60nm
o 1 single reading frame, structural genes at 5’ end, non-structural genes at 3’ end
o morphological structure remains unknown
o 6 genotypes (1-6) on basis of phylogenetic analysis
o 1 and 4 have poorer px and response to interferon tx
o In Hong Kong, 1 is 67%, 6 is 25%

68
Q

• How does HCV infect a cell?

A

o Binds receptor (also for LDL and VLDL)
o Enters in endosome → uncoated → genome replicated in cytoplasm
o → translated and produced in ER → golgi → combo w genome
o → exocytosis

69
Q

• What is geographic prevalence of HCV in blood donors?

A

o High (>5%): N African country
o Med: N Asia, brazil
o Low: N America, argentina, china, australia, S Africa, W Europe
o Very low: N Europe

70
Q

• What are risk factors assoc w HCV transmission?

A

o Transfusion or transplant from infx donor
o IV drugs
o Hemodialysis (yrs of tx)
o needles/sharps accidents
o Sex/household exposure to anti-HCV-positive contact
o Multiple sex partners
o Birth of HCV-infx mother

71
Q

• What are clinical features of HCV?

A
o	spectrum similar to chronic HBV, but w lower freq
o	Inc: avg 6-7 wks (r 2-26 wks)
o	Jaundice: r 20-40%
o	Chronic hepatitis: 70-85%
o	Persistent infx: 85-100%
o	Cirrhosis: 17%
o	HCC: 2%
o	Immunity: no known protective Ab response
72
Q

• what is typical serologic course of chronic HCV?

A

o ↑ALT (correlate w sxs) 1-5 mos, then oscillates for years

o a-HCV rises and plateaus at 1 yr

73
Q

• how is HCV infx diagnosed?

A

o 1) a-HCV: Not useful in acute phase, appears after 4 wks
o 2) HCV-RNA (qual or quant): via PCR and branched DNA. Mb dx in acute phase. Mainly to monitor response to antiviral tx
o HCV-Ag: EIA. Easiest for monitoring

74
Q

• What are prognostic tests for HCV infx?

A

o Genotyping: 1 & 4 have worse px, respond poorly to interferon tx (DNA sequencing, PCR-hybridization e.g. INNO-LIPA.)
o Serotyping: useful when no detectable RNA
o Viral Load: ↑ → poorer px; also monitor IFN tx

75
Q

• What is prevalence of a-HCV in US? Screening?

A

o Overall: 1.6%
o M»F, esp born 1945-65
o 76% of infected ppl are baby boomers → birth cohort screening by CDC
o Also higher in blacks

76
Q

• What is CDCs Hep C prevention strategy?

A

o Prevent new infxs: Risk-reduction education and awareness; Review and update infx control practices; Screen and test donors; Virus inactivation of plasma-derived products
o Reduce risk of liver dz w chronic: Identify and test persons at risk for HCV infx, Counseling, medical evaluation, management of infected ppl

77
Q

• What is HEV?

A

o Calicivirus-like viruses
o Unenveloped RNA virus, 32-34nm in diameter
o Single stranded RNA genome, 7.6 kb in size.
o Very labile and sensitive
o Can only be cultured recently

78
Q

• What are clinical features of HepE infx?

A

o Inc: avg 40 d (r 15-60)
o Fatality: 1-3% (if prego: 15-25%)
o Illness severity: ↑ w age
o Chronic sequelae: none

79
Q

• What is typical serologic course f HEV infx?

A

o Feval HEV, ALT, IgM-HEV 3-10 wks (correlate w sxs)

o IgG-HEV rises at 3 wks, plateaus at 10 wks

80
Q

• What are epidemiologic features of HEV?

A

o outbreaks usu assoc w fecal in water
o Several large epidemics in India, USSR, China, Africa, Mexico
o US and other nonendemic areas, no documented outbreaks, low prevalence of a-HEV (<2%) → unknown source of infx
o Minimal person-to-person transmission

81
Q

• What are prevention and control measures for travelers to HEV-endemic regions?

A

o Avoid drinking water (and beverages w ice) of unknown purity, uncooked shellfish, uncooked fruit/vegetables not peeled or prepared by self
o Igs prepared from donors in Western countries does not prevent infx
o Unknown efficacy of Ig prepared from donors in endemic areas